Meeting
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
Authors
Amit Jethanandani
The University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Amit Jethanandani , Nathan A. Hanson , Ifeanyichukwu Ogobuiro , Garrett Simpson , Christopher Montoya , Nesrin Dogan , John Chet Ford , Lorraine Portelance , Benjamin Spieler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 709)
DOI
10.1200/JCO.2024.42.3_suppl.709
Abstract #
709
Poster Bd #
N18
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.
First Author: Colin Hill
Poster
2021 Gastrointestinal Cancers Symposium
Long-term outcomes of a prospective single institution study with multiagent chemotherapy and stereotactic body radiation therapy in locally advanced or recurrent pancreatic adenocarcinoma.
First Author: Colin Hill
Poster
2018 Gastrointestinal Cancers Symposium
Neoadjuvant therapy outcomes in nonmetastatic pancreatic cancer.
First Author: Jeanette Muniz Kovtun
Poster
2015 ASCO Annual Meeting
Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.
First Author: Julia S. Johansen